Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;19(9):981-7.
doi: 10.1038/ejhg.2011.61. Epub 2011 Apr 13.

Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families

Affiliations

Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families

Mathieu Fiore et al. Eur J Hum Genet. 2011 Sep.

Abstract

The c.1544+1G>A substitution at the 5' splice donor site of intron 15 of the ITGA2B gene, called the French Gypsy mutation, causes Glanzmann thrombasthenia, an inherited hemorrhagic disorder transmitted as an autosomal recessive trait and characterized by an altered synthesis of the platelet αIIbβ3 integrin. So far, this mutation has only been found in affected individuals originating from French Manouche families, strongly suggesting a founder effect. Our goal was to investigate the origin of the French Gypsy mutation. We estimated the age of the mutation by a likelihood-based method that uses the length of the shared haplotypes among a set of patients. For this, we genotyped 23 individuals of Manouche origin; consisting of 9 Glanzmann thrombasthenia patients homozygous for the French Gypsy mutation, 6 heterozygous carriers and 8 homozygous wild-type individuals. They were genotyped for four single-nucleotide polymorphisms using high-resolution melting curve analysis, and for two CA repeats in the BRCA1 and THRA genes at chromosome 17, using fragment analysis gels. We found that a haplotype of five polymorphic loci covering a 4-cM region was strongly associated with the French Gypsy mutation, suggesting a founder effect. The estimated age of this founder mutation was 300-400 years (range 255-552 years). Thus, all carriers of the French Gypsy mutation c.1544+1G>A at intron 15 descended from a common ancestor 300-400 years ago.

PubMed Disclaimer

Figures

Figure 1
Figure 1
c.1544+1G>A mutation affects the splicing and expression of αIIb. (a) Schematic representation of the exon 15/intron 15 boundary of the ITGA2B gene showing the position of the c.1544+1G>A mutation (marked by red lines); (b) mRNA sequence showing the splice products. Eight base pair deletion causes a frameshift, which results in premature stop codon.
Figure 2
Figure 2
Pedigrees of studied cases of GT. Homozygous GT subjects are represented by solid squares or circles; heterozygous individuals by solid squares or circles within open frames. The bars represent the haplotype constructed from four SNPs and two STRs around the French Gypsy mutation of the ITGA2B gene.
Figure 3
Figure 3
Origin of the French Gypsy mutation. Origin of Gypsies formula image, European migration in Balkans formula image, migration in Germany formula image, introduction of the French Gypsy mutation in France and founder effect formula image.

Similar articles

Cited by

References

    1. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006;1:10. - PMC - PubMed
    1. Seligsohn U, Rososhansky S. A Glanzmann's thrombasthenia cluster among Iraqi Jews in Israel. Thromb Haemost. 1984;52:230–231. - PubMed
    1. Awidi AS. Increased incidence of Glanzmann's thrombasthenia in Jordan as compared with Scandinavia. Scand J Haematol. 1983;30:218–222. - PubMed
    1. Piippo K, Laitinen P, Swan H, et al. Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns. J Am Coll Cardiol. 2000;35:1919–1925. - PubMed
    1. Heyer E. One founder/one gene hypothesis in a new expanding population: saguenay (Quebec, Canada) Hum Biol. 1999;71:99–109. - PubMed

Publication types

Substances